| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 94.30 | 8 |
| Intrinsic value (DCF) | 35.84 | -59 |
| Graham-Dodd Method | 47.90 | -45 |
| Graham Formula | 43.10 | -51 |
Vetoquinol SA is a leading veterinary pharmaceutical company specializing in the development and sale of veterinary drugs and non-medicinal products for livestock and companion animals. Headquartered in Lure, France, and operating across Europe, the Americas, and the Asia Pacific, Vetoquinol serves diverse animal health needs, including mobility, dermatology, anti-parasite treatments, and infectious disease management. With a history dating back to 1933, the company has established itself as a trusted provider in the veterinary pharmaceutical sector, catering to cattle, sheep, pigs, poultry, and dogs. As a subsidiary of Soparfin SCA, Vetoquinol leverages its expertise in animal health to drive innovation and growth in a rapidly expanding global market. The company’s diversified product portfolio and strong regional presence position it well in the competitive veterinary healthcare industry.
Vetoquinol SA presents a stable investment opportunity within the veterinary pharmaceutical sector, supported by its diversified product portfolio and global footprint. The company’s solid financials, including €539.2 million in revenue and €58.7 million in net income for the fiscal year, reflect its operational efficiency. With a market capitalization of approximately €860 million and a beta of 0.783, Vetoquinol exhibits lower volatility compared to broader markets, appealing to risk-averse investors. The company’s strong cash position (€206.3 million) and manageable debt (€21.1 million) provide financial flexibility. However, investors should monitor competitive pressures in the veterinary pharmaceutical space and potential regulatory challenges in key markets. The dividend yield, supported by a €0.85 per share payout, adds to its attractiveness for income-focused investors.
Vetoquinol SA competes in the global veterinary pharmaceutical market, where differentiation is driven by product innovation, regulatory expertise, and geographic reach. The company’s competitive advantage lies in its diversified product portfolio, which spans multiple therapeutic areas, including mobility, dermatology, and infectious diseases. This diversification reduces reliance on any single product line and enhances resilience against market fluctuations. Vetoquinol’s strong presence in Europe and expanding footprint in the Americas and Asia Pacific provide a balanced revenue stream. However, the company faces intense competition from larger players like Zoetis and Elanco, which have greater R&D budgets and broader distribution networks. Vetoquinol’s mid-market positioning allows it to focus on niche segments and regional markets where it can leverage local expertise. The company’s subsidiary structure under Soparfin SCA provides financial stability but may limit agility compared to independent peers. Overall, Vetoquinol’s strategic focus on innovation and regional expansion positions it well, though it must continue to invest in R&D and marketing to maintain its competitive edge.